Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2018 pubmed

Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock.

Yamada. Noriaki N; Martin. Lukas B LB; Zechendorf. Elisabeth E; Purvis. Gareth S D GSD; Chiazza. Fausto F; Varrone. Barbara B; Collino. Massimo M; Shepherd. Joanna J; Heinbockel. Lena L; Gutsmann. Thomas T; Correa. Wilmar W; Brandenburg. Klaus K; Marx. Gernot G; Schuerholz. Tobias T; Brohi. Karim K; Thiemermann. Christoph C

Key Findings

  • Plasma LL‑37 levels are about 12‑times higher in trauma patients with hemorrhagic shock compared to healthy people.
  • High‑dose Pep19‑4LF given after resuscitation raised mean arterial pressure and reduced kidney, liver, and lung injury in shocked rats.
  • Pep19‑4LF blocks NF‑κB activation and lowers pro‑inflammatory cytokine release, likely via enhanced Akt and eNOS signaling.

Practical Outcomes

  • This isn’t a ready‑to‑use supplement for biohackers—Pep19‑4LF is still experimental and only tested in rats. However, the results suggest that synthetic LL‑37‑like peptides could become future therapies for severe blood loss and organ protection, so keep an eye on clinical trials for any human‑available versions.

Summary

In people with severe injury and bleeding, a natural immune peptide called LL‑37 shoots up in the blood. In rats, giving a lab‑made version of this peptide (Pep19‑4LF) after a big blood loss helped keep blood pressure up and protected the kidneys, liver, and lungs from damage. The protection seems to come from calming down inflammation pathways.

Abstract

To evaluate (1) levels of the host-defense/antimicrobial peptide LL-37 in patients with trauma and hemorrhagic shock (HS) and (2) the effects of a synthetic host-defense peptide; Pep19-4LF on multiple organ failure (MOF) associated with HS. HS is a common cause of death in severely injured patients. There is no specific therapy that reduces HS-associated MOF. (1) LL-37 was measured in 47 trauma/HS patients admitted to an urban major trauma center. (2) Male Wistar rats were submitted to HS (90 min, target mean arterial pressure: 27-32 mm Hg) or sham operation. Rats were treated with Pep19-4LF [66 (n = 8) or 333 μg/kg · h (n = 8)] or vehicle (n = 12) for 4 hours following resuscitation. Plasma LL-37 was 12-fold higher in patients with trauma/HS compared to healthy volunteers. HS rats treated with Pep19-4LF (high dose) had a higher mean arterial pressure at the end of the 4-hour resuscitation period (79 ± 4 vs 54 ± 5 mm Hg) and less renal dysfunction, liver injury, and lung inflammation than HS rats treated with vehicle. Pep19-4LF enhanced (kidney/liver) the phosphorylation of (1) protein kinase B and (2) endothelial nitric oxide synthase. Pep19-4LF attenuated the HS-induced (1) translocation of p65 from cytosol to nucleus, (2) phosphorylation of IκB kinase on Ser, and (3) phosphorylation of IκBα on Ser resulting in inhibition of nuclear factor kappa B and formation of proinflammatory cytokines. Pep19-4LF prevented the release of tumor necrosis factor alpha caused by heparan sulfate in human mononuclear cells by binding to this damage-associated molecular pattern. Trauma-associated HS results in release of LL-37. The synthetic host-defense/antimicrobial peptide Pep19-4LF attenuates the organ injury/dysfunction associated with HS.

Study Information

Provider

pubmed

Year

2018

DOI

10.1097/sla.0000000000002186